James M. Frates - 06 Jan 2022 Form 4/A - Amendment Insider Report for Amylyx Pharmaceuticals, Inc. (AMLX)

Role: Chief Financial Officer
Signature: /s/ Joshua B. Cohen, as Attorney in Fact for James Frates
Issuer symbol: AMLX
Transactions as of: 06 Jan 2022
Net transactions value: $0
Form type: 4/A - Amendment
Filing time: 26 Apr 2023, 19:34:34 UTC
Date Of Original Report: 10 Jan 2022
Previous filing: 17 Jun 2021
Next filing: 28 Mar 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	AMLX	Common Stock	Conversion of derivative security	$0	+19,482		$0.000000	19,482	06 Jan 2022	By Trust	F1, F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	AMLX	Series C-1 Preferred Stock	Conversion of derivative security	$0	-19,482	-100%	$0.000000^*	0	06 Jan 2022	Common Stock	19,482		By Trust	F1, F2, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Upon the closing of the Issuer's initial public offering, all shares of Series C-1 Preferred Stock automatically converted into the number of shares of the Issuer's Common Stock shown in column 4 of Table I without payment or further consideration. The Series C-1 Preferred Stock had no expiration date.
F2	This amendment on Form 4/A to the Form 4 originally filed on January 10, 2022 (the "Original Form 4") is being filed solely to report the conversion of 19,482 shares of Series C-1 Preferred Stock into shares of the Issuer's Common Stock upon the closing of the Issuer's initial public offering, which was inadvertently omitted from the Original Form 4.
F3	Shares held by the James M. Frates Grantor Retained Annuity Trust 2021, for which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose.